AbbVie closed a $10.9bn acquisition of Apogee, adding its inflammatory‑disease candidate to a portfolio that has long trailed behind rivals. The deal tops the company’s largest purchase in more than five years, underscoring a surge of mergers in the biopharma sector as firms chase pipeline depth.

Apogee’s lead candidate, an oral agent targeting cytokine pathways, has shown promise in early trials, offering AbbVie a foothold in a market dominated by biologics. The purchase also grants access to Apogee’s advanced manufacturing platform, which could shorten development timelines and reduce production costs for future assets. It diversifies AbbVie’s portfolio and boosts its competitive edge in a crowded market.

Market watchers view the deal as a signal that biopharma giants will increasingly turn to niche developers for breakthrough assets. Analysts note that the $10.9bn outlay could reshape pricing dynamics, as AbbVie leverages Apogee’s technology to streamline drug production. The transaction also places pressure on smaller firms to accelerate their own M&A strategies to stay competitive in the fast‑moving sector.